Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer (JBCRG-03)
Phase 2
- Conditions
- Operable breast cancer
- Registration Number
- JPRN-C000000291
- Lead Sponsor
- Japan Breast Cancer Research Group (JBCRG)
- Brief Summary
Of the 132 patients assessable for pathologic response, 23% experienced a pCR and 6% had a near pCR (few remaining cancer cells), resulting in a quasi-pCR of 29%. Clinical RR following the initial DOC regimen was 64%. The overall clinical RR after completion of FEC was 79%. Breast-conserving surgery was performed in 79% of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 137
Inclusion Criteria
Not provided
Exclusion Criteria
Drug hypersensitivity Severe complication Inflammatory breast cancer Double cancer Bilateral breast cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological responce, safety
- Secondary Outcome Measures
Name Time Method Clinical response, Breast conserving rate, Overall survival, Disease free survival